CSL plans flu vaccine BLA by 2007
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CSL plans to submit a BLA "within 12 months for both multi-dose vial and thimerosal-free single-dose" formulations of an influenza vaccine, the Australian firm announces Feb. 7. A clinical study is slated to begin "later this year." An early 2007 submission could put the CSL flu vaccine on the U.S. market in time for the 2007-2008 season; the firm plans to supply "up to 20 mil. doses to the U.S. as the expanded plant comes online in 2008," CSL says. The company has manufactured flu vaccine in its Melbourne facility since 1968...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.